Subscribe
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma
Articles
Articles
Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM
ASH 2015 - Multiple Myeloma
,
ASH Highlights
Conference Correspondent
Read More
FDA News - December 2015
FDA Approvals, News & Updates
December 2015, Vol 6, No 11
Read More
Keytruda (Pembrolizumab) First PD-1 Inhibitor Approved for the Treatment of Patients with Metastatic Non–Small-Cell Lung Cancer Expressing PD-L1
By
Lisa A. Raedler, PhD, RPh
Drug Updates
December 2015, Vol 6, No 11
Lung cancer is the leading cause of cancer-related mortality in the United States among men and women. The most common type of the disease, non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases.
Read More
Two Studies Point to Inadequate Evidence Supporting Many FDA Drug Approvals
By
Rosemary Frei, MSc
Health Policy
,
Policies & Guidelines
December 2015, Vol 6, No 11
Two related studies have documented significant deficiencies in the way the FDA approves expanded or new indications for drugs, using its expedited approval processes with limited evidence.
Read More
Getting to Value-Based Cancer Care in the ’Omics Era Requires Data Integration
By
Wayne Kuznar
Value-Based Care
December 2015, Vol 6, No 11
Washington, DC-An evolving knowledge of cancer biology and the availability of comprehensive genetic testing engender a need for tools that help oncologists integrate these data and select therapy, said Gary Palmer, MD, Chief Medical Officer, NantHealth, Los Angeles, CA, in delivering his keynote address at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read More
Promising Locoregional Therapies for Hepatocellular Carcinoma and Metastatic CRC
By
Walter Alexander
Emerging Therapies
,
Personalized Medicine
December 2015, Vol 6, No 11
Barcelona, Spain—Locoregional therapies for hepatocellular carcinoma and for colorectal cancer (CRC) metastases to the liver continue to demonstrate promising outcomes in clinical trials, according to findings presented at the 2015 European Society for Medical Oncology World Congress on Gastrointestinal Cancer.
Read More
Treating Sexual Dysfunction in Breast Cancer Survivors
By
Chase Doyle
Survivorship
,
Policies & Guidelines
December 2015, Vol 6, No 11
Sexual dysfunction is prevalent in women with breast cancer, a consequence of treatment that affects pre- and postmenopausal women. However, the safety and efficacy of available treatments remain understudied, according to Shari B. Goldfarb, MD, Medical Oncologist, Breast Medicine Service, Memorial Sloan Kettering Cancer Center (MSKCC), NY.
Read More
Addressing Fertility Issues in Patients with Breast Cancer
By
Chase Doyle
Survivorship
,
Policies & Guidelines
December 2015, Vol 6, No 11
Fertility and early menopause after cancer can pose challenging emotional and medical issues for patients and their clinicians. Survivors who become infertile because of their cancer treatment are at an increased risk for emotional distress and are often affected by unresolved grief and depression, according to Ann H. Partridge, MD, MPH, Medical Oncologist, Dana-Farber Cancer Institute, Boston.
Read More
Aprepitant Reduces Cough Severity in Patients with Lung Cancer
By
Meg Barbor, MPH
Lung Cancer
,
Solid Tumors
December 2015, Vol 6, No 11
Boston, MA—In a first-of-its-kind study, aprepitant (Emend), a centrally acting neurokinin (NK)-1 antagonist indicated for the treatment of chemotherapy-induced nausea and vomiting (CINV), led to a reduction in cough frequency and an improvement in the objective and subjective measures of cough in patients with lung cancer.
Read More
Teamwork Improves End-of-Life Care, Saves Money
By
Phoebe Starr
End-of-Life Care
,
Palliative Care
,
Policies & Guidelines
,
Personalized Medicine
December 2015, Vol 6, No 11
San Antonio, TX—An innovative care model program for end-of-life care for patients with cancer improved symptom management, reduced hospitalizations and in-hospital deaths, and increased the use of hospice care.
Read More
Page 174 of 329
171
172
173
174
175
176
177
Top Trending Articles
1.
ACCC Federal Policy Update Highlights Key Risks and Opportunities for Oncology Practices in 2026
Meg Barbor, MPH
2.
From Chaos to Clarity: Data-Driven Denial Prevention
Shawntea (Taya) Gordon, MBA, FACMPE
3.
The Evolving Landscape of Lung Cancer Care
Meg Barbor, MPH
Home
Issues
Online First
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
Value-Based Care in Myeloma